{
    "id": 271,
    "fullName": "EGFR exon 19 del",
    "impact": "deletion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EGFR exon 19 deletions are in-frame deletions within the kinase domain of Egfr (PMID: 16912195). EGFR exon 19 deletions result in increased EGFR kinase activity and induce oncogenic transformation of cells (PMID: 16912195; PMID: 17495523).",
            "references": [
                {
                    "id": 21,
                    "pubMedId": 16912195,
                    "title": "Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16912195"
                },
                {
                    "id": 22,
                    "pubMedId": 17495523,
                    "title": "Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17495523"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "exon 19 del",
    "createDate": "03/13/2014",
    "updateDate": "09/05/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15880,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a single patient diagnosed with lung spindle cell carcinoma harboring an EGFR exon 19 deletion was treated with Iressa (gefitinib), but no benefit was observed and therapy was discontinued after 14 days (PMID: 30555702).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4015,
                "name": "spindle cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13942,
                    "pubMedId": 30555702,
                    "title": "Lung spindle cell carcinoma harbouring a constitutively active epidermal growth factor receptor mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30555702"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21115,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (ARCHER 1050) trial, Vizimpro (dacomitinib) demonstrated superior efficacy compared to Iressa (gefitinib) as first-line therapy in non-small cell lung cancer patients harboring EGFR activating mutations (exon 19 deletion or L858R), resulting in prolonged overall survival (34.1 vs 26.8 months, HR=0.76, p=0.0438) (PMID: 29864379; NCT01774721).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11520,
                    "pubMedId": 29864379,
                    "title": "Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29864379"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12177,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ARCHER 1050) that supported FDA approval, treatment with Vizimpro (dacomitinib) as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 12.3 months with dacomitnib vs. 9.8 months with Iressa (gefitinib) among patients with EGFR exon 19 deletions (PMID: 28958502; NCT01777421).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10136,
                    "pubMedId": 28958502,
                    "title": "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28958502"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15471,
                    "pubMedId": null,
                    "title": "Vizimpro (dacomitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17008,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vizimpro (dacomitinib) is included in guidelines as first-line therapy for patients with advanced or metastatic non-small cell lung cancer harboring sensitizing EGFR mutations, such as EGFR exon 19 deletions (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 769,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with Vizimpro (dacomitinib) (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 448,
                    "pubMedId": null,
                    "title": "First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers",
                    "url": "http://meetinglibrary.asco.org/content/99805-114"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13930,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion demonstrated a partial response when treated with Tagrisso (osimertinib), which lasted for nearly 16 months (PMID: 29596911).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11362,
                    "pubMedId": 29596911,
                    "title": "Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29596911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10759,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 5610,
                "therapyName": "Gefitinib + Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8809,
                    "pubMedId": 22789825,
                    "title": "Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22789825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19633,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Lazertinib (YH25448) demonstrated safety and preliminary efficacy, resulted in objective response in 54% (69/127, 3 complete response, 66 partial response) and disease control in 87% (110/127) of patients with advanced non-small cell lung cancer harboring EGFR exon 19 deletion or L858R, with a median duration of response of 15.2 months and median progression-free survival of 9.5 months (PMID: 31587882; NCT03046992).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17335,
                    "pubMedId": 31587882,
                    "title": "Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31587882"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17596,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr signaling and viability of patient-derived cells and a cell line of non-small cell lung cancer harboring an EGFR exon 19 deletion mutation, resulted in tumor regression in patient-derived xenograft models (PMID: 30670498).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18127,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with SHR-A1307 demonstrated inhibition of cell growth in culture, and reduction of tumor volume and remission in xenograft models (PMID: 30962319).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8060,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9568,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2912,
                "therapyName": "AZD3759",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7282,
                    "pubMedId": 27928026,
                    "title": "AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27928026"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2551,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TH-4000 induced tumor regression in erlotinib-resistant human cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletion mutations (J Clin Oncol 33, 2015 (suppl; abstr e13548)).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2910,
                "therapyName": "TH-4000",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3281,
                    "pubMedId": null,
                    "title": "TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC.",
                    "url": "http://meetinglibrary.asco.org/content/153293-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18143,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring an EGFR exon 19 deletion treated with Nimotuzumab demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 830,
                "therapyName": "Nimotuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12974,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zykadia (ceritinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17630,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tarceva (erlotinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring an EGFR exon 19 deletion treated with Vectibix (panitumumab) demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 845,
                "therapyName": "Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19388,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (RELAY), Cyramza (ramucirumab) in combination with Tarceva (erlotinib) demonstrated improved progression-free survival compared to Tarceva (erlotinib) plus placebo (19.4 vs 12.4 months, HR=0.59, p<0.0001) in patients with advanced non-small cell lung cancer harboring EGFR exon 19 deletion mutations or L858R (PMID: 31591063; NCT02411448).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8339,
                "therapyName": "Erlotinib + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16943,
                    "pubMedId": 31591063,
                    "title": "Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31591063"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 770,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a comparison of the clinical outcomes of non-small cell lung cancer patients harboring either EGFR exon 19 deletion or L858R demonstrated similar responses to treatment with Iressa (gefitinib) or Tarceva (erlotinib), with overall response rates of 76.9% with Iressa (gefitinib) and 74.4% with Tarceva (erlotinib) (PMID: 24736073).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 449,
                    "pubMedId": 24736073,
                    "title": "Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24736073"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12833,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) compared to 47.3% (61/129) with Paraplatin (carboplatin) plus Taxol (paclitaxel) and prolonged progression-free survival (HR=0.48) in non-small cell lung cancer patients harboring EGFR activating mutations, including EGFR exon 19 deletions (PMID: 19692680, NCT00322452).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2375,
                    "pubMedId": 19692680,
                    "title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19692680"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15469,
                    "pubMedId": null,
                    "title": "Iressa (gefitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21130,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (ADJUVANT/CTONG1104) trial, adjuvant Iressa (gefitinib) treatment resulted in prolonged disease-free survival (28.7 vs 18.0 months, HR=0.60, p=0.0054) compared to Navelbine (vinorelbine) and Platinol (cisplatin) combination in completely resected non-small cell lung cancer patients harboring EGFR activating (L858R or exon 19 deletion) mutations (PMID: 29174310; NCT01405079).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18418,
                    "pubMedId": 29174310,
                    "title": "Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29174310"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20326,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (WJTOG 3405), first-line treatment with Iressa (gefitinib) resulted in an increased median progression-free survival of 9.2 months compared to 6.3 months with treatment with Platinol (cisplatin) and Taxotere (docetaxel) in non-small cell lung cancer patients harboring either EGFR L858R or an EGFR exon 19 deletion (PMID: 20022809).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17805,
                    "pubMedId": 20022809,
                    "title": "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20022809"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing an EGFR exon 19 deletion mutation (PMID: 30670498).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16833,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TUL-001 inhibited Egfr downstream signaling, resulted in tumor growth inhibition and prolonged overall survival in cell line xenograft models of non-small cell lung cancer brain metastasis harboring EGFR exon 19 deletion mutations (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1316).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8203,
                "therapyName": "TUL-001",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14948,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TUL-001, an EGFR inhibitor for the treatment of NSCLC with brain metastasis (BM).",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18075,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15990,
                    "pubMedId": 31086949,
                    "title": "EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31086949"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12978,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Alunbrig (brigatinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21112,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, progression-free survival at 4 months was 95.5% in patients with lung adenocarcinoma harboring activating EGFR mutations in exon 19 (n=25) and exon 21 (L858R n=19, E709V/L861Q n=1) following treatment with Vizimpro (dacomitinib), compared to 76.8% in the overall treatment population (PMID: 25456362; NCT00818441).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 714,
                "therapyName": "Dacomitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3046,
                    "pubMedId": 25456362,
                    "title": "Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25456362"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 771,
            "approvalStatus": "Clinical Study - Meta-analysis",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a meta-analysis, 12 Phase III trials investigating EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 450,
                    "pubMedId": 24533047,
                    "title": "Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24533047"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18057,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR tyrosine kinase inhibitor treatment including icotinib (n=5) resulted in partial response in 77.8% (14/18) and stable disease in 22.2% (4/18) of non-small cell lung cancer patients harboring EGFR L858R (n=16) or exon 19 deletion mutations (n=2), with a median progression-free survival of 10.5 months (PMID: 30791921).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20438,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (INCREASE) trial, icotinib treatment resulted in a median progression-free survival of 12.5 months and an objective response rate of 75% (48/64) in patients with treatment-naive non-small cell lung cancer patients harboring EGFR exon 19 deletions (PMID: 32060099; NCT02404675).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17841,
                    "pubMedId": 32060099,
                    "title": "Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32060099"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13967,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Imbruvica (ibrutinib) inhibited Egfr activity and downstream signaling, resulting in cell cycle arrest in culture and delayed tumor progression in cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletions (PMID: 26375053).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11393,
                    "pubMedId": 26375053,
                    "title": "Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26375053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16560,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer (NSCLC) patient harboring an EGFR exon 19 deletion demonstrated 82% tumor shrinkage following treatment with TAS-121, and in preclinical experiments, TAS-121 inhibited proliferation of a NSCLC cell line harboring an EGFR exon 19 deletion in culture and inhibited tumor growth in xenograft models (PMID: 30872380).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8103,
                "therapyName": "TAS-121",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14625,
                    "pubMedId": 30872380,
                    "title": "TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30872380"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18072,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (NCI 9303), Cometriq (cabozantinib) and Tarceva (erlotinib) combination treatment resulted in an objective response rate of 10.8% (4/37, 4 partial response) and an 8-week disease control rate of 67.0% (25/37) in heavily pretreated non-small cell lung cancer patients harboring EGFR mutations, progression-free survival and overall survival were not different among patients harboring EGFR L858R, exon 19 deletion, or T790M (PMID: 30915273; NCT01866410).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15983,
                    "pubMedId": 30915273,
                    "title": "Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30915273"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15172,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iressa (gefitinib) and Alimta (pemetrexed) combination treatment resulted in a median progression-free survival (PFS) of 6.7 months, an objective response rate of 22.9% (8/35), and an overall survival of 24.3 months in non-small cell lung cancer patients harboring sensitizing EGFR mutations (15 exon 19 deletion, 20 L858R) who progressed on first-line Iressa (gefitinib) treatment, with no difference in PFS between exon 19 deletion and L858R groups (5.6 vs 7.0 months) (PMID: 30268482).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 7457,
                "therapyName": "Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12770,
                    "pubMedId": 30268482,
                    "title": "Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268482"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3928,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11318,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20224,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Paraplatin (carboplatin) and Alimta (pemetrexed) to Iressa (gefitinib) improved progression-free survival (16 vs 8 mo, HR=0.51, p<0.001) and overall survival (not reached vs 17 mo, HR=0.45, p<0.001) in patients with metastatic non-small cell lung cancer harboring EGFR activating mutations, including EGFR exon 19 deletion, L858R, L861Q, and G719X, but also resulted in higher incidence of clinically relevant toxicity (51% vs 25%, p<0.001) (PMID: 31411950).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8501,
                "therapyName": "Carboplatin + Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17741,
                    "pubMedId": 31411950,
                    "title": "Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31411950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18128,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with Tarceva (erlotinib) demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5304,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (ASPIRATION) trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 11.0 months for patients harboring EGFR exon 19 deletions (PMID: 26720423; NCT01310036).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4999,
                    "pubMedId": 26720423,
                    "title": "First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26720423"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 724,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (EURTAC) that supported FDA approval, treatment with Tarceva (erlotinib) resulted in improved progression-free survival compared to treatment with platinum-based chemotherapy in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2334,
                    "pubMedId": 24868098,
                    "title": "U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24868098"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15472,
                    "pubMedId": null,
                    "title": "Tarceva (erlotinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21142,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (RADIANT) trial, a trend toward favorable disease free survival (46.4 vs 28.5 months, HR=0.61, p=0.039) was observed in non-small cell lung cancer patients harboring EGFR L858R or exon 19 deletion mutations when treated with Tarceva (erlotinib) vs placebo in the adjuvant setting, but significance was not demonstrated due to study design (PMID: 26324372; NCT00373425).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4546,
                    "pubMedId": 26324372,
                    "title": "Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26324372"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7505,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17236,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DZD9008 inhibited proliferation of tumor cells expressing EGFR exon 19 deletion mutation in culture, resulted in tumor growth inhibition and regression in cell line xenograft and patient-derived xenograft (PDX) models (AACR Annual Meeting 2019, Abstract 3081).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 8430,
                "therapyName": "DZD9008",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15248,
                    "pubMedId": null,
                    "title": "DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/7519"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13973,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited Egfr activation, resulting in growth inhibition of non-small cell lung cancer cells harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 19447865).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11395,
                    "pubMedId": 19447865,
                    "title": "Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19447865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18664,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243; NCT01562028).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8747,
                    "pubMedId": 28408243,
                    "title": "Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28408243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19391,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tarceva (erlotinib) in combination with (bevacizumab) did not significantly improve progression-free survival (17.9 vs 13.5 months, HR=0.81, p=0.39), objective response rate (81% vs 83%, p=0.81), or overall survival (32.4 vs 50.6 months, HR=1.41, p=0.33) compared to Tarceva (erlotinib) alone in patients with non-small cell lung cancer harboring EGFR exon 19 deletion or L858R (PMID: 31393548; NCT01532089).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16945,
                    "pubMedId": 31393548,
                    "title": "Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31393548"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5649,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring an exon 19 deletion in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring an exon 19 deletion (PMID: 26825170).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5135,
                    "pubMedId": 26825170,
                    "title": "EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26825170"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6161,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (LUX-Lung 7) trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months, HR=0.73, p=0.017) and time-to-treatment failure (13.7 vs 11.5 months, HR=0.73, p=0.0073) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334; NCT01466660).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5321,
                    "pubMedId": 27083334,
                    "title": "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27083334"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 33,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial supporting FDA approval (LUX-Lung 3), Gilotrif (afatinib) treatment resulted in improved median progression-free survival compared to chemotherapy (HR=0.28) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (PMID: 23816960; NCT00949650).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2368,
                    "pubMedId": 23816960,
                    "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15470,
                    "pubMedId": null,
                    "title": "Gilotrif (afatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21146,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (LUX-Lung 7) trial, Gilotrif (afatinib) resulted in overall survival similar to Iressa (gefitinib) (HR=0.86, p=0.2580) in patients with non-small cell lung cancer harboring EGFR L858R or exon 19 deletion mutations, updated analysis indicated improved progression free survival (11.0 vs 10.9 mo, HR=0.74, p=0.0178), time-to-treatment failure (13.7 vs 11.5 mo, HR=0.75, p=0.0136), and objective response rate (72.5% vs 56%, OR=2.121, p=0.0018) (PMID: 28426106; NCT01466660).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18426,
                    "pubMedId": 28426106,
                    "title": "Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28426106"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7502,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited growth of transformed cells expressing EGFR exon 19 deletion in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1329).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14954,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing EGFR exon 19 deletion mutation demonstrated sensitivity to TAS6417 in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21040,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR signaling and proliferation of non-small cell lung cancer cell lines harboring EGFR exon 19 deletion mutations in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 31092564).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20644,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, first-line treatment with the combination of Iressa (gefitinib) and Alimta (pemetrexed) resulted a median overall survival of 43.4 months, compared to 36.8 with Iressa (gefitinib) alone, and prolonged median progression-free survival compared to Iressa (gefinitib) (16.2 mo. vs 11.1 mo; HR=0.67) in patients with non-squamous non-small cell lung cancer patients with activating EGFR mutations (primarily L858R and exon 19 deletion mutations) (PMID: 31605797).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 7457,
                "therapyName": "Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17975,
                    "pubMedId": 31605797,
                    "title": "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31605797"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18077,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15990,
                    "pubMedId": 31086949,
                    "title": "EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31086949"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12964,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Alecensa (alectinib) is not indicated for use in non-small cell lung cancer patients with sensitizing EGFR mutations (including exon 19 deletions and L858R) who relapsed on EGFR tyrosine kinase inhibitor therapy (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion in culture that had, over time, acquired resistance to Tarceva (erlotinib) showed decreased drug resistance when treatment was combined with Filgotinib (GLPG0634), demonstrating reduced expression of Osmr and phosphorylated-Stat3, and decreased cell viability (PMID: 28729401).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 6457,
                "therapyName": "Erlotinib + GLPG0634",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10327,
                    "pubMedId": 28729401,
                    "title": "JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28729401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14488,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro and inhibition of tumor growth in cell line xenograft models (PMID: 29754184).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8970,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6826,
                    "pubMedId": 27435396,
                    "title": "Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27435396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7253,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 4428,
                "therapyName": "Gefitinib + K-756",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6261,
                    "pubMedId": 27196752,
                    "title": "The Discovery and Characterization of K-756, a Novel Wnt/\u03b2-Catenin Pathway Inhibitor Targeting Tankyrase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196752"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12952,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tagrisso (osimertinib) is included in guidelines as first-line therapy for locally advanced or metastatic non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2159,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549; NCT01802632).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2666,
                    "pubMedId": 25923549,
                    "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923549"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16792,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (FLAURA) trial, treatment with Tagrisso (osimertinib) resulted in a longer median time to discontinuation of treatment (23.0 vs 16.0 months) and second progression-free survival (not reached vs 20.0 months, HR=0.58, p=0.0004) compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) inpreviously untreated non-small cell lung cancer patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 30659024; NCT02296125).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14914,
                    "pubMedId": 30659024,
                    "title": "Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30659024"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8968,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6826,
                    "pubMedId": 27435396,
                    "title": "Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27435396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18129,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion treated with Tagrisso (osimertinib) demonstrated inhibition of cell growth in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19666,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (FLAURA) trial, treatment with Tagrisso (osimertinib) in previously untreated non-small cell lung cancer patients harboring either EGFR L858R or an exon 19 deletion resulted in a median overall survival of 38.6 months, compared to 31.8 months with a comparator (gefitinib or erlotinib), and at 3 years, 28% (79/279) were receiving the trial regimen in the Tagrisso (osimertinib) group vs. 9% (26/277) with the comparator (PMID: 31751012; NCT02296125).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17452,
                    "pubMedId": 31751012,
                    "title": "Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31751012"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12672,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (FLAURA) trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in a longer median progression-free survival compared to treatment with either Tarceva (erlotinib) or Iressa (gefitinib) (18.9 mo vs 10.2 mo) in previously untreated non-small cell lung cancer patients harboring either EGFR L858R or EGFR exon 19 deletion (PMID: 29151359; NCT02296125).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10585,
                    "pubMedId": 29151359,
                    "title": "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29151359"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15473,
                    "pubMedId": null,
                    "title": "Tagrisso (osimertinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19747,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, first-line treatment with Iressa (gefitinib) plus Glucophage (metformin) in non-diabetic non-small cell lung cancer patients harboring EGFR mutations, primarily exon 19 deletions and L858R, did not result in increased median progression-free survival compared to Iressa (gefitinib) plus placebo (10.3 mo vs. 11.4 mo with placebo), and resulted in similar median overall survival (22.0 mo vs. 27.5 mo) and objective response rate (66% vs. 66.7%) (PMID: 31413010; NCT01864681).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 9206,
                "therapyName": "Gefitinib + Metformin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17541,
                    "pubMedId": 31413010,
                    "title": "Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31413010"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17629,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iressa (gefitinib) is included in guidelines as first-line therapy for advanced, recurrent, or metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18076,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, or anti-CTLA with anti-PD-1) resulted in significantly reduced overall response rate (7%, 5/76 vs 22%, 47/212, p=0.002), progression-free survival (wild-type vs exon 19 deletion, HR=0.449, p<0.001), and overall survival (HR=0.69, p=0.03) in non-small cell lung cancer patients harboring EGFR exon 19 deletions compared to EGFR wild-type patients (PMID: 31086949).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15990,
                    "pubMedId": 31086949,
                    "title": "EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31086949"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17628,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gilotrif (afatinib) is included in guidelines as first-line, but not subsequent therapy for metastatic nonsquamous non-small cell lung carcinoma patients harboring sensitizing EGFR mutations, including exon 19 deletion and L858R (NCCN.org).",
            "molecularProfile": {
                "id": 367,
                "profileName": "EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5746,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5757,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5755,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5754,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3694,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15874,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EGFR C797S was identified as an acquired mutation in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M at disease progression while on Olmutinib (HM61713) treatment (PMID: 26749488).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13881,
                    "pubMedId": 26749488,
                    "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26749488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5744,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15869,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated an initial partial response to treatment with Nazartinib (CO-1686), however, demonstrated progression in the liver followed by the thorax, and progression in the thorax was coincident with emergence of an EGFR C797S mutation (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17664,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) did not inhibit viability of patient-derived non-small cell lung cancer cells harboring EGFR C797S, EGFR exon 19 deletion, and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5756,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5758,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3692,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis were resistant to Tagrisso (osimertinib) in culture (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15498,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, acquired EGFR C797S mutations were identified in post-treatment samples of 6 non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M who progressed on Tagrisso (osimertinib) (PMID: 30228210).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 13403,
                    "pubMedId": 30228210,
                    "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30228210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20697,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, EGFR C797S was detected in non-small cell lung cancer patients harboring EGFR exon 19 deletions and EGFR T790M with acquired resistance to Tagrisso (osimertinib) (PMID: 31911548).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5747,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3921,
                "therapyName": "Gefitinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3695,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3996,
                    "pubMedId": 25939061,
                    "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5760,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture, and reduction of tumor volume and remission in xenograft models following treatment with SHR-A1307 (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18134,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR C797S, EGFR T790M and EGFR exon 19 deletion mutations in-cis demonstrated inhibition of cell growth in culture following treatment with Tarceva (erlotinib) (PMID: 30962319).",
            "molecularProfile": {
                "id": 14858,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 381,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of the anti-ERBB3 (HER3) antibody A3 and Tykerb (lapatinib) resulted in increased growth inhibition in non-small cell lung cancer cells harboring both EGFR exon 19 deletion and EGFR T790M and with ERBB3 (HER3) over expression in culture compared to Tykerb (lapatinib) alone (PMID: 23896512).",
            "molecularProfile": {
                "id": 17817,
                "profileName": "EGFR exon 19 del EGFR T790M ERBB3 over exp"
            },
            "therapy": {
                "id": 3496,
                "therapyName": "A3 + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 82,
                    "pubMedId": 23896512,
                    "title": "Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23896512"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4478,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4477,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4476,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18231,
                "profileName": "EGFR exon 19 del NRAS E63K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4474,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4500,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18232,
                "profileName": "EGFR exon 19 del EGFR T790M KRAS amp"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4480,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18233,
                "profileName": "EGFR exon 19 del KRAS amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4481,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18233,
                "profileName": "EGFR exon 19 del KRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4483,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18234,
                "profileName": "EGFR exon 19 del NRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4482,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18234,
                "profileName": "EGFR exon 19 del NRAS amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4484,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18234,
                "profileName": "EGFR exon 19 del NRAS amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4486,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18236,
                "profileName": "EGFR exon 19 del NRAS Q61K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4485,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18236,
                "profileName": "EGFR exon 19 del NRAS Q61K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4487,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18236,
                "profileName": "EGFR exon 19 del NRAS Q61K"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4488,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion, and amplification of NRAS, MAPK1, and CRKL in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4489,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplification of NRAS, MAPK1, and CRKL were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18237,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4490,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18238,
                "profileName": "EGFR exon 19 del NRAS G12V"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4492,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18239,
                "profileName": "EGFR exon 19 del NRAS G12R"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4491,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18239,
                "profileName": "EGFR exon 19 del NRAS G12R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4494,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18240,
                "profileName": "EGFR exon 19 del EGFR T790M NRAS Q61K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9236,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9238,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4496,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion and amplification of CRKL and MAPK1 were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 18262,
                "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14761,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR exon 19 deletion with EGFR C797S demonstrated resistance to inhibition by Poziotinib (HM781-36B) in culture (PMID: 29686424).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11486,
                    "pubMedId": 29686424,
                    "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29686424"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5753,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5752,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5762,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5763,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5761,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5751,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 21570,
                "profileName": "EGFR exon 19 del EGFR C797S"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18060,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and icotinib (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9532,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18067,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3145,
                    "pubMedId": 17463250,
                    "title": "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17463250"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18058,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21050,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment combined with Iressa (gefitinib) induced cell death of an Iressa (gefitinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification in culture, and induced tumor regression in a cell line xenograft model (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 7415,
                "therapyName": "Capmatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18059,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9531,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17902,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with Iressa (gefitinib)-resistant lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated improvement in symptoms and decrease in tumor size following treatment with Tarceva (erlotinib) and Avastin (bevacizumab) (PMID: 30792648).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15864,
                    "pubMedId": 30792648,
                    "title": "Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30792648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9533,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression (PMID: 27694386; NCT02143466).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21049,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment led to tumor stasis for more than 3 weeks in a cell line xenograft model of lung cancer harboring an EGFR exon 19 deletion and a MET amplification (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26445,
                "profileName": "EGFR exon 19 del KRAS G12S"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9534,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size and continued clinical benefit 5 months after the start of therapy (PMID: 27694386).",
            "molecularProfile": {
                "id": 26887,
                "profileName": "EGFR exon 19 del MET D1228V MET amp"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16633,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression and MET D1228V was identified as an acquired mutation (PMID: 27694386; NCT02143466).",
            "molecularProfile": {
                "id": 26887,
                "profileName": "EGFR exon 19 del MET D1228V MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10678,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to Tagrisso (osimertinib) therapy inhibited growth of a Tagrisso (osimertinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M with YES1 amplification and over expression in culture, and reduced tumor growth in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27724,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of YES1 in a lung cancer cell line with an EGFR exon 19 deletion and T790M promoted acquired resistance to Tagrisso (osimertinib) in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27725,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 over exp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing EGFR exon 19 deletion mutation in combination with T790M demonstrated sensitivity to TAS6417 in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16692,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, 83% (5/6) of non-small cell lung cancer patients harboring EGFR exon 19 deletions that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3591,
                    "pubMedId": 18981003,
                    "title": "Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18981003"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3929,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung cancer cell lines harboring both EGFR T790M and EGFR exon 19 deletion mutations, and decreased tumor size in xenograft models (PMID: 26090892).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13952,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Iressa (gefitinib) treatment resulted in initial response in a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion, however, the disease progressed 3 years after initial treatment and EGFR T790M was identified at the time of progression (PMID: 29704676).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11378,
                    "pubMedId": 29704676,
                    "title": "Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29704676"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21138,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, EGFR T790M was identified at disease progression in 54% (19/35) of non-small cell lung cancer patients harboring EGFR L858R (n=20) or exon 19 deletions (n=15) who received Iressa (gefitinib) as first-line treatment (PMID: 30268482).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12770,
                    "pubMedId": 30268482,
                    "title": "Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268482"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5936,
                "therapyName": "GSK2334470 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15867,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686) (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21134,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Iressa (gefitinib) and pemetrexed resulted in a median progression-free survival (PFS) of 6.7 months and an objective response rate of 22.9% (8/35) in non-small cell lung cancer patients harboring EGFR L858R (n=20) or EGFR exon 19 deletion mutations (n=15) who progressed on Iressa (gefitinib), with no difference in PFS between exon 19 deletion and L858R groups (5.6 vs 7.0 months), or T790M positive (n=19) and negative (n=16) groups (5.9 vs 7.0 months) (PMID: 30268482).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 7457,
                "therapyName": "Gefitinib + Pemetrexed",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12770,
                    "pubMedId": 30268482,
                    "title": "Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268482"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5939,
                "therapyName": "Bosutinib + Osimertinib + PF-573228",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited Egfr phosphorylation and viability of transformed cells expressing both EGFR T790M and an EGFR exon 19 deletion mutation (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14129,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cyramza (ramucirumab) and Tagrisso (osimertinib) combination treatment resulted in an objective response rate of 76% (19/25, 1 complete response, 18 partial response), and stable disease in 16% (4/25) of EGFR-mutant (exon 19 deletion or L858R) non-small cell lung cancer patients harboring EGFR T790M, who progressed on first-line EGFR TKI therapy (J Clin Oncol 36, 2018 (suppl; abstr 9053); NCT02789345).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4379,
                "therapyName": "Osimertinib + Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11473,
                    "pubMedId": null,
                    "title": "Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.",
                    "url": "https://meetinglibrary.asco.org/record/160827/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8969,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tagrisso (osimertinib) obtained through a Phase I/II trial (AURA) resulted in a partial response and stable disease of brain metastases in a non-small cell lung cancer patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396; NCT01802632).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6826,
                    "pubMedId": 27435396,
                    "title": "Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27435396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2157,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tagrisso (osimertinib) treatment resulted in a response rate of 64% (49/77) in non-small cell lung cancer patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549; NCT01802632).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2666,
                    "pubMedId": 25923549,
                    "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923549"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17632,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, treatment-naive non-small cell lung cancer patients harboring both EGFR exon 19 deletion mutations and ultra-low level EGFR T790M as detected by ddPCR demonstrated improved progression-free survival (39.5 vs 11.7 months, p=0.001) after first-generation tyrosine kinase inhibitor therapy compared to patients who did not harbor both mutations (PMID: 30936123).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 6870,
                "therapyName": "unspecified EGFR tyrosine kinase inhibitor",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15701,
                    "pubMedId": 30936123,
                    "title": "Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30936123"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18043,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of Sprycel (dasatinib) and Gilotrif (afatinib) demonstrated manageable toxicity, reduced allele frequencies of EGFR T790M and EGFR activating mutations (exon 19 deletion and L858R) in ctDNA, but only resulted in stable disease as best response in 26% of non-small cell lung cancer patients acquired resistance to tyrosine kinase inhibitors (PMID: 30880334; NCT01999985).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1351,
                "therapyName": "Afatinib + Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15971,
                    "pubMedId": 30880334,
                    "title": "Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30880334"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13965,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Abivertinib (AC0010) treatment resulted in an overall response rate of 36.5% (19/52) and a disease control rate of 75% (39/52) in non-small cell lung carcinoma patients harboring EGFR exon 19 deletions (33/52) or L858R (19/52) with acquired resistance to first generation Egfr tyrosine kinase inhibitors, 87% (45/52) of the patients also harbored EGFR T790M (PMID: 29626621).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2909,
                "therapyName": "Abivertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11390,
                    "pubMedId": 29626621,
                    "title": "First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell\u00a0Lung Cancer: Safety, Efficacy, and Potential\u00a0Mechanism of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29626621"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR harboring both exon 19 deletion and T790M in culture (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4520,
                "therapyName": "EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11306,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5937,
                "therapyName": "Osimertinib + TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5750,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17623,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, third-line treatment with Tagrisso (osimertinib) resulted in improved median progression-free survival compared to treatment with the combination of Taxotere (docetaxel) and Avastin (bevacizumab) (10.2 mo vs. 2.95 mo., HR=0.23), and a an overall response rate of 61.6% (45/73) compared to 8.3% (6/72), in patients with non-squamous non-small cell lung cancer harboring EGFR T790M with either EGFR L858R or an EGFR exon 19 deletion (PMID: 29858027, NCT02959749).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 80521,
                "name": "lung non-squamous non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11751,
                    "pubMedId": 29858027,
                    "title": "Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29858027"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) treatment delayed emergence of resistance tumor in cell line xenograft models of non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation and expressing EGFR T790M (PMID: 19447865).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11395,
                    "pubMedId": 19447865,
                    "title": "Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19447865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10689,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BELIEF), Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243; NCT01562028).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8747,
                    "pubMedId": 28408243,
                    "title": "Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28408243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5748,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17666,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Lazertinib (YH25448) treatment resulted in a 49.3% reduction of intracranial tumor and a 12.7% reduction of the extracranial tumor in a patient with non-small cell lung cancer harboring both EGFR exon 19 deletion mation and EGFR T790M (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4912,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients treated with Gilotrif (afatinib) that acquired resistance, with 9 of those patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4789,
                    "pubMedId": 26862733,
                    "title": "The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26862733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung cancer cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 3075,
                "therapyName": "WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3620,
                    "pubMedId": 25964297,
                    "title": "The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964297"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11303,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4580,
                    "pubMedId": 25870145,
                    "title": "Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25870145"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Poziotinib (HM781-36B) inhibited viability of a non-small cell lung carcinoma cell line harboring EGFR exon 19 deletion and T790M in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20087,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, patients with non-small cell lung cancer harboring both EGFR T790M and an EGFR exon 19 deletion demonstrated a higher response rate (complete or partial), 61% (63/103) vs 35% (16/46), and slightly higher median progression-free survival, 9.6 months vs 7.2 months, than those patients harboring both EGFR T790M and EGFR L858R (PMID: 31954624; NCT02108964).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17702,
                    "pubMedId": 31954624,
                    "title": "Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31954624"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5938,
                "therapyName": "Osimertinib + PF-573228 + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14489,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 del and EGFR T790M , resistant to Iressa (gefitinib) and Tarceva (erlotinib), were sensitive to treatment with OBX1-012, demonstrating decreased cell viability and apoptosis in vitro (PMID: 29754184).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 7094,
                "therapyName": "OBX1-012",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11644,
                    "pubMedId": 29754184,
                    "title": "Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29754184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19635,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Lazertinib (YH25448) demonstrated safety and preliminary efficacy, resulted in higher objective response (57%, 62/108 vs 37%, 7/19) and longer median progression-free survival (9.5 vs 5.4 months) in patients with EGFR T790M -positive non-small cell lung cancer harboring EGFR activating mutations (exon 19 deletion or L858R) compared to T790M-negative patients (PMID: 31587882; NCT03046992).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17335,
                    "pubMedId": 31587882,
                    "title": "Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31587882"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17598,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lazertinib (YH25448) inhibited viability of patient-derived cells and a cell line of non-small cell lung cancer harboring both EGFR T790M and an EGFR exon 19 deletion mutation, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30670498).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 8558,
                "therapyName": "Lazertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15689,
                    "pubMedId": 30670498,
                    "title": "YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30670498"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4521,
                "therapyName": "Cetuximab + EAI045",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6436,
                    "pubMedId": 27251290,
                    "title": "Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27251290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3120,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3633,
                    "pubMedId": 25923550,
                    "title": "Rociletinib in EGFR-mutated non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25923550"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 5935,
                "therapyName": "Buparlisib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAS6417 inhibited viability of a non-small cell lung carcinoma cell line harboring EGFR exon 19 deletion and T790M in culture (PMID: 31467113).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 6994,
                "therapyName": "CLN-081",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16160,
                    "pubMedId": 31467113,
                    "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31467113"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15873,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Olmutinib (HM61713) resulted in partial response after 2 cycles of treatment and was continued for 17 months until disease progression in a patient with lung adenocarcinoma harboring EGFR exon 19 deletion and T790M (PMID: 26749488).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 2137,
                "therapyName": "Olmutinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13881,
                    "pubMedId": 26749488,
                    "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26749488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 27945,
                "profileName": "EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11302,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquisition of YES1 amplification in a lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M was associated with resistance to Tagrisso (osimertinib) in culture and in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27946,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13931,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).",
            "molecularProfile": {
                "id": 29877,
                "profileName": "BRAF V600E EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11362,
                    "pubMedId": 29596911,
                    "title": "Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29596911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Sprycel (dasatinib) in culture, resulting in decreased AKT and ERK phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 1351,
                "therapyName": "Afatinib + Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Sprycel (dasatinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142)",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 7028,
                "therapyName": "Afatinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14138,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29949,
                "profileName": "EGFR exon 19 del YES1 act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Tagrisso (osimertinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in YES1, leading to increased expression and phosphorylation of Yes1, demonstrated sensitivity to the combination of Tagrisso (osimertinib) and Saracatinib (AZD0530) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 7029,
                "therapyName": "Osimertinib + Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14148,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased phosphorylation of Met, were associated with resistance to Gilotrif (afatinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14150,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion and with transposon insertions in MET, leading to increased Met phosphorylation, demonstrated sensitivity to the combination of Gilotrif (afatinib) and Xalkori (crizotinib) in culture, resulting in decreased Akt and Erk phosphorylation and reduced cell viability (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 3378,
                "therapyName": "Afatinib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transposon insertions in MET, leading to increased expression and phosphorylation of Met, were associated with resistance to Tarceva (erlotinib) in a lung adenocarcinoma cell line harboring an EGFR exon 19 deletion in culture (PMID: 29875142).",
            "molecularProfile": {
                "id": 29950,
                "profileName": "EGFR exon 19 del MET act mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11478,
                    "pubMedId": 29875142,
                    "title": "YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29875142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).",
            "molecularProfile": {
                "id": 29952,
                "profileName": "EGFR exon 19 del ERBB2 wild-type"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11487,
                    "pubMedId": 29298799,
                    "title": "Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298799"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14228,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A were resistant to treatment with Tagrisso (osimertinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14226,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Iressa (gefitinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14227,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon 19 del, and EGFR T854A demonstrated a decreased response to Gilotrif (afatinib) in culture when compared to Alunbrig (brigatinib) (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR C797S, EGFR exon19 del, and EGFR T854A were sensitive to treatment with Alunbrig (brigatinib) in culture, demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29956,
                "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Gilotrif (afatinib), demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14305,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EGFR exon 19 del and EGFR T854A were sensitive to treatment with Tagrisso (osimertinib), demonstrating reduced cell growth (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14309,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Alunbrig (brigatinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR exon 19 del and EGFR T854A were moderately resistant to Iressa (gefitinib) in culture (PMID: 29702287).",
            "molecularProfile": {
                "id": 29981,
                "profileName": "EGFR exon 19 del EGFR T854A"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11550,
                    "pubMedId": 29702287,
                    "title": "Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29702287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14431,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells, known to harbor EGFR exon 19 del (PMID: 26515464), expressing MTOR E2419K were sensitive to the combined therapy of Tarceva (erlotinib) and AZD8055, demonstrating inhibition of EGFR downstream signaling in vitro and tumor shrinkage in cell line xenograft models (PMID: 29530932).",
            "molecularProfile": {
                "id": 30016,
                "profileName": "EGFR exon 19 del MTOR E2419K"
            },
            "therapy": {
                "id": 7089,
                "therapyName": "AZD8055 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11632,
                    "pubMedId": 29530932,
                    "title": "Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29530932"
                },
                {
                    "id": 11633,
                    "pubMedId": 26515464,
                    "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14417,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells, known to harbor EGFR exon 19 del (PMID: 26515464), expressing MTOR E2419K were resistant to treatment with AZD8055 both in culture and in cell line xenograft models (PMID: 29530932).",
            "molecularProfile": {
                "id": 30016,
                "profileName": "EGFR exon 19 del MTOR E2419K"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11632,
                    "pubMedId": 29530932,
                    "title": "Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29530932"
                },
                {
                    "id": 11633,
                    "pubMedId": 26515464,
                    "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14413,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma cells, known to harbor EGFR exon 19 del (PMID: 26515464), expressing MTOR E2419K were resistant to treatment with Tarceva (erlotinib), demonstrating enhanced cell survival in culture and in cell line xenograft models (PMID: 29530932).",
            "molecularProfile": {
                "id": 30016,
                "profileName": "EGFR exon 19 del MTOR E2419K"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11632,
                    "pubMedId": 29530932,
                    "title": "Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29530932"
                },
                {
                    "id": 11633,
                    "pubMedId": 26515464,
                    "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR K754E in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to decreased response to Tarceva (erlotinib) compared to control cells in culture (PMID: 27478040).",
            "molecularProfile": {
                "id": 30469,
                "profileName": "EGFR exon 19 del EGFR K754E"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 8124,
                    "pubMedId": 27478040,
                    "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR S645C in lung adenocarcinoma cells harboring EGFR exon 19 deletion mutations led to resistance to Tarceva (erlotinib) in culture (PMID: 27478040).",
            "molecularProfile": {
                "id": 30470,
                "profileName": "EGFR exon 19 del EGFR S645C"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8124,
                    "pubMedId": 27478040,
                    "title": "High-throughput Phenotyping of Lung Cancer Somatic Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27478040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15499,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, loss of EGFR T790M and acquired PIK3CA E418K and E542K mutations were identified in a post-treatment sample from a patient harboring an EGFR exon 19 deletion who progressed on Tagrisso (osimertinib) treatment (PMID: 30228210).",
            "molecularProfile": {
                "id": 31070,
                "profileName": "EGFR exon 19 del PIK3CA E418K PIK3CA E542K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13403,
                    "pubMedId": 30228210,
                    "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30228210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15738,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Tarceva (erlotinib) (PMID: 24468202).",
            "molecularProfile": {
                "id": 31187,
                "profileName": "EGFR exon 19 del PTEN mut"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9964,
                    "pubMedId": 24468202,
                    "title": "Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24468202"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15739,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PTEN mutations were associated with a lower overall response rate of 7.3% in lung adenocarcinoma patients harboring EGFR exon 19 deletions or L858R, compared to 70.9% (p=0.061) in patients with wild-type PTEN, following treatment with EGFR tyrosine kinase inhibitors including Iressa (gefitinib) (PMID: 24468202).",
            "molecularProfile": {
                "id": 31187,
                "profileName": "EGFR exon 19 del PTEN mut"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9964,
                    "pubMedId": 24468202,
                    "title": "Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24468202"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15812,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion developed resistance to Tagrisso (osimertinib) and sequencing of circulating DNA identified gained CCDC6-RET and TPM3-NTRK1 fusions (PMID: 30257958).",
            "molecularProfile": {
                "id": 31240,
                "profileName": "CCDC6 - RET TPM3 - NTRK1 EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15813,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma (NSCLC) harboring an EGFR exon 19 deletion was found to have acquired an CCDC6-RET fusion, which was identified upon resistance to Tagrisso (osimertinib), and preclinical analysis of a NSCLC cell line harboring an EGFR exon 19 deletion and expressing CCDC6-RET also demonstrated resistance when treated with Tagrisso (osimertinib) in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15816,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion and a CCDC6-RET fusion had 78% tumor shrinkage at 8-weeks with a response lasting more than 3.5 months upon treatment with combined Tagrisso (osimertinib) and BLU-667, and in a NSCLC cell line harboring an EGFR exon 19 deletion and expressing a CCDC6-RET fusion the same treatment regimen decreased viability and reduced Ret, Akt, and Erk1/2 phosphorylation in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7752,
                "therapyName": "BLU-667 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined BLU-667 and Gilotrif (afatinib) treatment resulted in decreased viability and reduced Ret, Akt, and Erk1/2 phosphorylation in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing a CCDC6-RET fusion in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7753,
                "therapyName": "Afatinib + BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15814,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of a CCDC6-RET fusion in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion resulted in increased viability and Ret, Akt, and Erk1/2 phosphorylation relative to control when treated with Gilotrif (afatinib) in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15830,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined treatment with Cometriq (cabozantinib) and Tagrisso (osimertinib) resulted in decreased viability and Ret, Akt, and Erk1/2 phosphorylation in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing a CCDC6-RET fusion in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9250,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two non-small cell lung cancer patients harboring EGFR exon 19 deletions were found to have acquired CCDC6-RET fusions following progression on Tarceva (erlotinib) (PMID: 26187428).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7049,
                    "pubMedId": 26187428,
                    "title": "Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26187428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment of a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing a CCDC6-RET fusion with the RET inhibitor BLU-667 did not effect Akt or Erk phosphorylation or impact cell proliferation in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15828,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion and a CCDC6-RET fusion had stable disease at 1 month, but had disease progression at 2.5 months, when treated with Tarceva (erlotinib) and Cometriq (cabozantinib), in combination (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined treatment with Cometriq (cabozantinib) and Gilotrif (afatinib) resulted in decreased viability and Ret, Akt, and Erk1/2 phosphorylation in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing a CCDC6-RET fusion in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31241,
                "profileName": "CCDC6 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7420,
                "therapyName": "Afatinib + Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15824,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In clinical study, EGFR L798I was identified at disease progression in a patients with non-small cell lung cancer harboring both EGFR T790M and EGFR exon 19 deletion treated with Rociletinib (CO-1686), consistent with structural modeling prediction in which EGFR L798I in cis with T790M interfered with Rociletinib (CO-1686) binding (PMID: 27283993).",
            "molecularProfile": {
                "id": 31247,
                "profileName": "EGFR exon 19 del EGFR T790M EGFR L798I"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15829,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion and an NCOA4-RET fusion had tumor shrinkage of 78% at 8-weeks and a response lasting more than 3.5 months, when treated with Tagrisso (osimertinib) and BLU-667, in combination (PMID: 30257958).",
            "molecularProfile": {
                "id": 31250,
                "profileName": "NCOA4 - RET EGFR exon 19 del"
            },
            "therapy": {
                "id": 7752,
                "therapyName": "BLU-667 + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer cell lines harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion were resistant to growth inhibition by Tafinlar (dabrafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19689,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion demonstrated progression in the mediastinal lymph nodes after 1.5 years of treatment with Tarceva (erlotinib) and was found to have an acquired AGK-BRAF fusion (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion was resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15836,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion developed resistance to Tagrisso (osimertinib) treatment and was found to have gained an AGK-BRAF fusion (PMID: 30257958).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY3009120 inhibited growth and resulted in increased apoptotic signaling in a lung cancer cell line harboring an EGFR exon 19 deletion and expressing an AGK-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of an AGK-BRAF fusion in lung cancer cell lines harboring an EGFR exon 19 deletion conferred resistance to Tagrisso (osimertinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 31251,
                "profileName": "AGK - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15835,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring an EGFR exon 19 deletion developed resistance to combined Tagrisso (osimertinib) and Gemzar (gemcitabine) treatment and was found to have gained a BAIAP2L1-BRAF fusion (PMID: 30257958).",
            "molecularProfile": {
                "id": 31252,
                "profileName": "BAIAP2L1 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15868,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M demonstrated a partial response to treatment with Nazartinib (CO-1686), but developed progression in the liver after 11 months, and a post-progression biopsy identified the EGFR exon 19 deletion without EGFR T790M, and emergence of BRAF V600E (PMID: 30123863; NCT02108964).",
            "molecularProfile": {
                "id": 31305,
                "profileName": "BRAF V600E EGFR exon 19 del"
            },
            "therapy": {
                "id": 1309,
                "therapyName": "Nazartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13872,
                    "pubMedId": 30123863,
                    "title": "Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30123863"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15950,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (<2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31338,
                "profileName": "EGFR exon 19 del TMB low"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15953,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with low or intermediate tumor mutational burden (< 2.83 mutations/Mb or 2.84-4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a longer time to therapy discontinuation and greater overall survival compared to patients with high tumor mutational burden (>4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31338,
                "profileName": "EGFR exon 19 del TMB low"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15954,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with high tumor mutational burden (>4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a shorter time to therapy discontinuation (10 mo vs 17 and 16 mo) and shorter overall survival (21 mo vs 41 and 37 mo) compared to patients with low or intermediate tumor mutational burden (<2.83 mutations/Mb or 2.84-4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31339,
                "profileName": "EGFR exon 19 del TMB high"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15957,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung carcinoma patients with high tumor mutational burden (>4.85 mutations/Mb) harboring either EGFR exon 19 deletion or EGFR L858R demonstrated a shorter time to therapy discontinuation (10 mo vs 17 and 16 mo) and shorter overall survival (21 mo vs 41 and 37 mo) compared to patients with low or intermediate tumor mutational burden (<2.83 mutations/Mb or 2.84-4.85 mutations/Mb) when treated with either Tarceva (erlotinib) or Gilotrif (afatinib) (PMID: 30045933).",
            "molecularProfile": {
                "id": 31339,
                "profileName": "EGFR exon 19 del TMB high"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14072,
                    "pubMedId": 30045933,
                    "title": "Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045933"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15841,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived non-small cell lung carcinoma cell line harboring an EGFR exon 19 deletion and a PCBP2-BRAF fusion was resistant to Tafinlar (dabrafenib) in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31501,
                "profileName": "PCBP2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15842,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived non-small cell lung carcinoma cell line harboring an EGFR exon 19 deletion, and a PCBP2-BRAF fusion was resistant to LXH254 treatment in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31501,
                "profileName": "PCBP2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 4442,
                "therapyName": "LXH 254",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15844,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived non-small cell lung carcinoma cell line harboring an EGFR exon 19 deletion, and a PCBP2-BRAF fusion was sensitive to Mekinist (trametinib) treatment in culture (PMID: 30257958).",
            "molecularProfile": {
                "id": 31501,
                "profileName": "PCBP2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15839,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung carcinoma harboring an EGFR exon 19 deletion and an EGFR T790M mutation, treated with Tagrisso (osimertinib), was found to have lost the EGFR T790M mutation and acquired a PCBP2-BRAF fusion in liver metastases, and subsequently progressed (PMID: 30257958).",
            "molecularProfile": {
                "id": 31501,
                "profileName": "PCBP2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12495,
                    "pubMedId": 30257958,
                    "title": "Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30257958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of ANKRD1 was identified following acquired resistance to Tagrisso (osimertinib) in culture in two lung adenocarcinoma cell lines each harboring an EGFR exon 19 deletion, and one of these two cell lines was re-sensitized by ANKRD1 knockdown (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16145,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment resulted in decreased Ankrd1 expression and induction of apoptosis in two Gilotrif (afatinib)-resistant and two Tagrisso (osimertinib)- resistant lung adenocarcinoma cell lines harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16146,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) restored sensitivity of Gilotrif (afatinib) treatment in two lung adenocarcinoma cell lines each harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 7908,
                "therapyName": "Afatinib + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16147,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) treatment restored sensitivity to Tagrisso (osimertinib) treatment in two lung adenocarcinoma cell lines harboring an EGFR exon 19 deletion and overexpressing ANKRD1 in culture (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 7909,
                "therapyName": "Imatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of ANKRD1 was identified following acquired resistance to Gilotrif (afatinib) in culture in two lung adenocarcinoma cell lines harboring EGFR exon 19 deletions, and these cells were re-sensitized by ANKRD1 knockdown (PMID: 30291293).",
            "molecularProfile": {
                "id": 31511,
                "profileName": "ANKRD1 over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14283,
                    "pubMedId": 30291293,
                    "title": "Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30291293"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing an EGFR exon 19 deletion, EGFR L718V, and EGFR T790M demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 29571986).",
            "molecularProfile": {
                "id": 32794,
                "profileName": "EGFR exon 19 del EGFR L718V EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15765,
                    "pubMedId": 29571986,
                    "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29571986"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17899,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, patients with MET-positive non-small lung cancer harboring either EGFR L858R or an EGFR exon 19 deletion demonstrated a median progression-free survival of 8.9 mo., median overall survival of 15.6 mo., and an overall response rate of 68.9% (all partial responses) following first-line therapy with Tarceva (erlotinib) and Onartuzumab; however, the trial was terminated early due to lack of efficacy with the therapy in another trial and thus, the results are not conclusive (PMID: 30472556).",
            "molecularProfile": {
                "id": 32878,
                "profileName": "EGFR exon 19 del MET pos"
            },
            "therapy": {
                "id": 1280,
                "therapyName": "Erlotinib + Onartuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 15862,
                    "pubMedId": 30472556,
                    "title": "First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30472556"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and Mekinist (trametinib) resulted in greater cell death than Tagrisso (osimertinib) alone in non-small cell lung cancer cells harboring an EGFR exon 19 deletion and expressing BRAF G469A in culture (PMID: 31502118).",
            "molecularProfile": {
                "id": 34023,
                "profileName": "BRAF G469A EGFR exon 19 del"
            },
            "therapy": {
                "id": 8996,
                "therapyName": "Osimertinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16909,
                    "pubMedId": 31502118,
                    "title": "Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31502118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19300,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Selumetinib (AZD6244) inhibited proliferation of non-small cell lung cancer cells harboring an EGFR exon 19 deletion and expressing BRAF G469A and resulted in increased cell death and both decreased cell migration and Mapk pathway signaling compared to treatment with Tagrisso (osimertinib) in vitro (PMID: 31502118).",
            "molecularProfile": {
                "id": 34023,
                "profileName": "BRAF G469A EGFR exon 19 del"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16909,
                    "pubMedId": 31502118,
                    "title": "Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31502118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19301,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring an EGFR exon 19 deletion and expressing BRAF G469A were resistant to treatment with Tagrisso in culture (PMID: 31502118).",
            "molecularProfile": {
                "id": 34023,
                "profileName": "BRAF G469A EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16909,
                    "pubMedId": 31502118,
                    "title": "Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31502118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib (AZD6244) resulted in greater cell death than Tagrisso (osimertinib) alone in non-small cell lung cancer cells harboring an EGFR exon 19 deletion and expressing BRAF G469A in culture (PMID: 31502118).",
            "molecularProfile": {
                "id": 34023,
                "profileName": "BRAF G469A EGFR exon 19 del"
            },
            "therapy": {
                "id": 2225,
                "therapyName": "Osimertinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16909,
                    "pubMedId": 31502118,
                    "title": "Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31502118"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19373,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III trial (FLAURA), Tagrisso (osimertinib) treatment improved progression-free survival compared to Iressa (gefitinib) or Tarceva (erlotinib) in treatment naive patients with non-small cell lung cancer harboring EGFR exon 19 deletion or L858R, regardless of CD274 (PD-L1) expression level (PMID: 31605792; NCT02296125).",
            "molecularProfile": {
                "id": 34054,
                "profileName": "CD274 pos EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16928,
                    "pubMedId": 31605792,
                    "title": "Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31605792"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19657,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer co-harboring EGFR E709G and an EGFR exon 19 deletion demonstrated a partial response with a progression-free survival of 77.4 mo and an overall survival of 104.6 mo when treated with Iressa (gefitinib) (PMID: 27785061).",
            "molecularProfile": {
                "id": 34389,
                "profileName": "EGFR exon 19 del EGFR E709G"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17447,
                    "pubMedId": 27785061,
                    "title": "Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27785061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19690,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic lung adencarcinoma harboring an EGFR exon 19 deletion and EGFR T790M progressed after 9.5 months of Tagrisso (osimertinib) therapy, and was found to have acquired an AGK-BRAF fusion (PMID: 30831205).",
            "molecularProfile": {
                "id": 34422,
                "profileName": "AGK - BRAF EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19706,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tagrisso (osimertinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19712,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Nexavar (sorafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19700,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a lung cancer patient-derived xenograft (PDX) cell line harboring an EGFR exon 19 deletion and a PJAR-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 8996,
                "therapyName": "Osimertinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19711,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tafinlar (dabrafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19708,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Zelboraf (vemurafenib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19707,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition by Gilotrif (afatinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19713,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LY3009120 inhibited growth and resulted in increased apoptotic signaling and decreased MEK and ERK phosphorylation in a lung cancer patient-derived xenograft (PDX) cell line harboring an EGFR exon 19 deletion and a PJAR-BRAF fusion in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19709,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition by Iressa (gefitinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19705,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by Tarceva (erlotinib) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19710,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) cell line harboring and EGFR exon 19 deletion and a PJA2-BRAF fusion demonstrated resistance to growth inhibition and induction of apoptotic signaling by RXDX-105 (CEP-32496) in culture (PMID: 30831205).",
            "molecularProfile": {
                "id": 34438,
                "profileName": "PJA2 - BRAF EGFR exon 19 del"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17475,
                    "pubMedId": 30831205,
                    "title": "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30831205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19900,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and via cell free DNA testing was found to harbor an EGFR exon 19 deletion, EGFR T790M, EGFR T854A, and CCDC6-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 34663,
                "profileName": "CCDC6 - RET EGFR exon 19 del EGFR T790M EGFR T854A"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19904,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and was found via cell free DNA testing to harbor EGFR T790M, an EGFR exon 19 deletion, STRN-ALK, and CCDC6-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 34664,
                "profileName": "CCDC6 - RET STRN - ALK EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19908,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and was found via cell free DNA testing to harbor EGFR G724S, an EGFR exon 19 deletion, CTNNB1 S45P, and CCDC6-RET (PMID: 31300450).",
            "molecularProfile": {
                "id": 34665,
                "profileName": "CCDC6 - RET CTNNB1 S45P EGFR exon 19 del EGFR G724S"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19907,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tarceva (erlotinib) and was found via cell free DNA testing to EGFR T790M, an EGFR exon 19 deletion, CTNNB1 S33C, and CTNNB1 S33P (PMID: 31300450).",
            "molecularProfile": {
                "id": 34666,
                "profileName": "CTNNB1 S33C CTNNB1 S33P EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19910,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tagrisso (osimertinib) and was found via cell free DNA testing to harbor an EGFR exon 19 deletion, CCDC6-RET, and CTNNB1 S33C (PMID: 31300450).",
            "molecularProfile": {
                "id": 34667,
                "profileName": "CCDC6 - RET CTNNB1 S33C EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19914,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with an advanced solid tumor developed resistance to treatment with Tagrisso (osimertinib) and was found via cell free DNA testing to harbor an EGFR exon 19 deletion, TRIM24-RET, and RB1 R7fs (PMID: 31300450).",
            "molecularProfile": {
                "id": 34672,
                "profileName": "TRIM24 - RET EGFR exon 19 del RB1 R7fs"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17588,
                    "pubMedId": 31300450,
                    "title": "Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31300450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20700,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, an ALK fusion was detected in a non-small cell lung cancer patient harboring an EGFR exon 19 deletion and EGFR T790M with acquired resistance to Tagrisso (osimertinib) (PMID: 31911548).",
            "molecularProfile": {
                "id": 35294,
                "profileName": "ALK fusion EGFR exon 19 del EGFR T790M"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20709,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR S768_V769delinsIL conferred resistance to growth inhibition by Tagrisso (osimertinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35298,
                "profileName": "EGFR exon 19 del EGFR S768_V769delinsIL"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20711,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET H1094R conferred resistance to Tagrisso (osimertinib) in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35299,
                "profileName": "EGFR exon 19 del MET H1094R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20710,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MET H1094Y conferred resistance to Tagrisso (osimertinib) in a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35300,
                "profileName": "EGFR exon 19 del MET H1094Y"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20722,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tagrisso (osimertinib) synergistically inhibited growth of a non-small cell lung cancer cell line harboring an EGFR exon 19 deletion and expressing MET H1094Y in culture (PMID: 31911548).",
            "molecularProfile": {
                "id": 35300,
                "profileName": "EGFR exon 19 del MET H1094Y"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL were resistant to Tagrisso (osimertinib) in culture (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL were resistant to Tarceva (erlotinib) in culture (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21042,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Naquotinib (ASP8273) inhibited EGFR and AXL signaling and proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion mutations and overexpressing AXL in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 31092564).",
            "molecularProfile": {
                "id": 35512,
                "profileName": "AXL over exp EGFR exon 19 del"
            },
            "therapy": {
                "id": 1082,
                "therapyName": "Naquotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18203,
                    "pubMedId": 31092564,
                    "title": "Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21307,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) decreased EGFR phosphorylation levels and inhibited growth of lung adenocarcinoma cells harboring EGFR exon 19 deletion and EGFR amplification in culture (PMID: 32130260).",
            "molecularProfile": {
                "id": 36194,
                "profileName": "EGFR exon 19 del EGFR amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21308,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) decreased EGFR phosphorylation levels and inhibited growth of lung adenocarcinoma cells harboring EGFR exon 19 deletion and EGFR amplification in culture (PMID: 32130260).",
            "molecularProfile": {
                "id": 36194,
                "profileName": "EGFR exon 19 del EGFR amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18612,
                    "pubMedId": 32130260,
                    "title": "Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32130260"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 367,
            "profileName": "EGFR exon 19 del",
            "profileTreatmentApproaches": [
                {
                    "id": 154,
                    "name": "EGFR Inhibitor 1st gen",
                    "profileName": "EGFR exon 19 del"
                },
                {
                    "id": 263,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR exon 19 del"
                },
                {
                    "id": 264,
                    "name": "EGFR Inhibitor 2nd gen",
                    "profileName": "EGFR exon 19 del"
                },
                {
                    "id": 4596,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "EGFR exon 19 del"
                },
                {
                    "id": 69,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "EGFR exon 19 del"
                }
            ]
        },
        {
            "id": 14858,
            "profileName": "EGFR exon 19 del EGFR T790M EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17817,
            "profileName": "EGFR exon 19 del EGFR T790M ERBB3 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18231,
            "profileName": "EGFR exon 19 del NRAS E63K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18232,
            "profileName": "EGFR exon 19 del EGFR T790M KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18233,
            "profileName": "EGFR exon 19 del KRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18234,
            "profileName": "EGFR exon 19 del NRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18236,
            "profileName": "EGFR exon 19 del NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18237,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp NRAS amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18238,
            "profileName": "EGFR exon 19 del NRAS G12V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18239,
            "profileName": "EGFR exon 19 del NRAS G12R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18240,
            "profileName": "EGFR exon 19 del EGFR T790M NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18241,
            "profileName": "EGFR exon 19 del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18262,
            "profileName": "CRKL amp EGFR exon 19 del MAPK1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21570,
            "profileName": "EGFR exon 19 del EGFR C797S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24186,
            "profileName": "EGFR exon 19 del TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25627,
            "profileName": "EGFR exon 19 del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26445,
            "profileName": "EGFR exon 19 del KRAS G12S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26887,
            "profileName": "EGFR exon 19 del MET D1228V MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27724,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27725,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27945,
            "profileName": "EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27946,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29877,
            "profileName": "BRAF V600E EGFR exon 19 del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29949,
            "profileName": "EGFR exon 19 del YES1 act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29950,
            "profileName": "EGFR exon 19 del MET act mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29952,
            "profileName": "EGFR exon 19 del ERBB2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29956,
            "profileName": "EGFR exon 19 del EGFR C797S EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29981,
            "profileName": "EGFR exon 19 del EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30016,
            "profileName": "EGFR exon 19 del MTOR E2419K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30469,
            "profileName": "EGFR exon 19 del EGFR K754E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30470,
            "profileName": "EGFR exon 19 del EGFR S645C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31070,
            "profileName": "EGFR exon 19 del PIK3CA E418K PIK3CA E542K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31187,
            "profileName": "EGFR exon 19 del PTEN mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31240,
            "profileName": "CCDC6 - RET TPM3 - NTRK1 EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31241,
            "profileName": "CCDC6 - RET EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31247,
            "profileName": "EGFR exon 19 del EGFR T790M EGFR L798I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31250,
            "profileName": "NCOA4 - RET EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31251,
            "profileName": "AGK - BRAF EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31252,
            "profileName": "BAIAP2L1 - BRAF EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31253,
            "profileName": "PCBP2 - BRAF EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31305,
            "profileName": "BRAF V600E EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31338,
            "profileName": "EGFR exon 19 del TMB low",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31339,
            "profileName": "EGFR exon 19 del TMB high",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31501,
            "profileName": "PCBP2 - BRAF EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31511,
            "profileName": "ANKRD1 over exp EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31731,
            "profileName": "EGFR exon 19 del TP53 exon8",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32794,
            "profileName": "EGFR exon 19 del EGFR L718V EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32878,
            "profileName": "EGFR exon 19 del MET pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34023,
            "profileName": "BRAF G469A EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34054,
            "profileName": "CD274 pos EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34389,
            "profileName": "EGFR exon 19 del EGFR E709G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34422,
            "profileName": "AGK - BRAF EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34438,
            "profileName": "PJA2 - BRAF EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34663,
            "profileName": "CCDC6 - RET EGFR exon 19 del EGFR T790M EGFR T854A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34664,
            "profileName": "CCDC6 - RET STRN - ALK EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34665,
            "profileName": "CCDC6 - RET CTNNB1 S45P EGFR exon 19 del EGFR G724S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34666,
            "profileName": "CTNNB1 S33C CTNNB1 S33P EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34667,
            "profileName": "CCDC6 - RET CTNNB1 S33C EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34672,
            "profileName": "TRIM24 - RET EGFR exon 19 del RB1 R7fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35294,
            "profileName": "ALK fusion EGFR exon 19 del EGFR T790M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35298,
            "profileName": "EGFR exon 19 del EGFR S768_V769delinsIL",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35299,
            "profileName": "EGFR exon 19 del MET H1094R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35300,
            "profileName": "EGFR exon 19 del MET H1094Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35512,
            "profileName": "AXL over exp EGFR exon 19 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 36194,
            "profileName": "EGFR exon 19 del EGFR amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}